Takeda Pharmaceutical Company Limited

Pfizer Corporation

Calithera Biosciences, Inc.

Rongliang Chen

Zhe Nie

Naoki Yoshikawa

Betty Lam

Scott Channing Sutton

Srinivasa Reddy Natala

Colin O'Bryan

Tomonori Ichibakase

Simon Paul Planken

Mark E Adams

Chunrong Ma

Christopher Frederick Matthews

Kentaro Yaji

Hajime Motoyoshi

Lu Zeng

Padma Manam

Matthew Lardy

Steven James Wilkens

Colin O'bryan

Christopher Matthews

Disclosed is a complex of a compound of Formula 1, a stereoisomer thereof, or a tautomer of the compound of Formula 1 or stereoisomer thereof, and a cyclodextrin, in which the complex is an amorphous solid. This disclosure also relates to materials and methods for preparing the complex, to pharmaceutical compositions which contain the complex, and to the use of the complex to treat Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.

Isoquinolinyl triazolone complexes

Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof. Also disclosed are methods of using the chemical entities to treat disorders such as a cancer.

Solid state forms of fused heteroaromatic pyrrolidinones

The present invention provides compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, methods for their preparation, methods for their use, and pharmaceutical formulations comprising them.

Therapeutic compounds

Growing community of inventors

San Diego, CA, United States of America

Rongliang Chen